Education
About Us
Working with TipRanks
Follow Us
Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
ELDN Stock Chart & Stats
$2.21
-$0.17(-3.66%)
At close: 4:00 PM EST
$2.21
-$0.17(-3.66%)
Day’s Range― - ―
52-Week Range$1.35 - $4.97
Previous CloseN/A
Volume121.23K
Average Volume (3M)685.44K
Market Cap
$171.19M
Enterprise Value$129.54M
Total Cash (Recent Filing)$93.40M
Total Debt (Recent Filing)$722.00K
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 19, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding75,084,694
10 Day Avg. Volume571,181
30 Day Avg. Volume685,440
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.23
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.47K
Enterprise Value/Ebitda-1.40
Forecast
1Y Price Target
$7.75Price Target Upside250.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Kidney Function OutcomesTegoprubart produced among the highest mean kidney function levels reported in transplant trials, suggesting a potential advantage in preserving graft performance relative to current therapies.
Regulatory PathwayCompany plans to pursue a Phase III kidney transplantation program following regulatory discussions, which could accelerate development and provide clearer approval and data requirements if agreed.
Safety ProfileClinical data show a differentiated safety profile for tegoprubart with fewer opportunistic infections and lower rates of metabolic, neurologic, and cardiovascular toxicities compared with standard care, which could attract clinicians focused on long-term patient health.
Bears Say
Efficacy EvidenceEGFR improvements were not statistically superior to tacrolimus in the study, weakening the strength of efficacy claims that could support widespread adoption.
Market Adoption RiskA higher composite event rate for tegoprubart versus tacrolimus and investor disappointment over lack of clear superiority could reduce market penetration assumptions and pressure revenue forecasts.
Trial Size UncertaintyThe small number of patients in the study limits confidence that observed benefits will hold in a larger population, increasing clinical and commercial risk.
Eledon Pharmaceuticals News
ELDN FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was $1.35 and its highest was $4.96 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is $171.19M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Mar 19, 2026 which is in 42 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Nov 14, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.036.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -0.2.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 75,084,694 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -7.955%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in ELDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.75 (250.68% Upside)
$7.75 (250.68% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 871.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.9%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.55%
12-Months-Change
Fundamentals
Return on Equity
-95.49%
Trailing 12-Months
Asset Growth
13.34%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELDN Stock 12 Month Forecast
Average Price Target
$7.75
▲(250.68% Upside)
Technical Analysis
Tvardi Therapeutics
―
Editas Medicine
―
Annexon Biosciences
―
Design Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
12.00% Insiders
6.15% Mutual Funds
0.04% Other Institutional Investors
74.56% Public Companies and
Individual Investors